“From 1 January the medicine Xalkori® (crizotinib) will made available through the Pharmaceutical Benefits Scheme (PBS) for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Without the PBS subsidy the drug … Continue reading Crizotinib approved for ROS1 in Australia
Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!
To all ROS1+ non-small cell lung cancer (NSCLC) patients in the United Kingdom (UK): Please help advocate for coverage of crizotinib (Xalkori) for ROS1+ NSCLC through the UK’s national health system. The Roy Castle Lung Cancer Foundation is putting together a submission on behalf of ROS1+ patients, and they are looking for patient experience quotes, preferably from the … Continue reading ROS1+ lung cancer patients in United Kingdom: we need your help!